A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19

The ARCADIA Trial is a randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes, hospitalised with COVID-19.

开始日期2020-08-12

申办/合作机构

St George Street Capital Ltd.

NCT05216172

/ Completed临床2期

AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce

AZD1656 in Transplantation with Diabetes tO PromoTe Immune TOleraNce: a single site, placebo-controlled, double-blind randomised clinical trial of AZD1656 in renal transplant patients with Type 2 diabetes

开始日期2019-12-13

申办/合作机构

Queen Mary University of London

[+1]

EUCTR2019-001587-30-GB

/ Unknown status临床2期

AZD1656 in Transplantation with Diabetes tO PromoTe Immune TOleraNce - The ADOPTION Study

开始日期2019-07-26

申办/合作机构

Queen Mary University of London

100 项与 AZD-1656 相关的临床结果

登录后查看更多信息

100 项与 AZD-1656 相关的转化医学

登录后查看更多信息

100 项与 AZD-1656 相关的专利（医药）

登录后查看更多信息

项与 AZD-1656 相关的文献（医药）

2024-11-01·Biochemical Pharmacology

Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants

Article

作者: Ford, Brian E. ; Oakley, Fiona ; Smith, David M. ; Ford, Brian E ; Fairclough, Rebecca J ; Agius, Loranne ; Fairclough, Rebecca J. ; Chachra, Shruti S ; Alshawi, Ahmed ; Chachra, Shruti S. ; Smith, David M ; Tiniakos, Dina

Glucokinase activators (GKAs) have been developed as blood glucose lowering drugs for type 2 diabetes. Despite good short-term efficacy, several GKAs showed a decline in efficacy chronically during clinical trials. The underlying mechanisms remain incompletely understood. We tested the hypothesis that deficiency in the liver glucokinase regulatory protein (GKRP) as occurs with common human GCKR variants affects chronic GKA efficacy. We used a Gckr-P446L mouse model for the GCKR exonic rs1260326 (P446L) variant and the Gckr-del/wt mouse to model transcriptional deficiency to test for chronic efficacy of the GKA, AZD1656 in GKRP-deficient states. In the Gckr-P446L mouse, the blood glucose lowering efficacy of AZD1656 (3 mg/kg body wt) after 2 weeks was independent of genotype. However after 19 weeks, efficacy was maintained in wild-type but declined in the LL genotype, in conjunction with raised hepatic glucokinase activity and without raised liver lipids. Sustained blood glucose lowering efficacy in wild-type mice was associated with qualitatively similar but more modest changes in the liver transcriptome compared with the P446L genotype, consistent with GKA therapy representing a more modest glucokinase excess than the P446L genotype. Chronic treatment with AZD1656 in the Gckr-del/wt mouse was associated with raised liver triglyceride and hepatocyte microvesicular steatosis. The results show that in mouse models of liver GKRP deficiency in conjunction with functional liver glucokinase excess as occurs in association with common human GCKR variants, GKRP-deficiency predisposes to declining efficacy of the GKA in lowering blood glucose and to GKA induced elevation in liver lipids.

2023-06-01·Liver Research

Glucokinase activator improves glucose tolerance and induces hepatic lipid accumulation in mice with diet-induced obesity

Article

作者: Cai, Nan ; Chen, Xuanrong ; Zeng, Longyi ; Liu, Jia ; Wen, Siyin ; Shi, Guojun ; Lin, Shuo ; Zeng, Wen ; Wen, Zheyao ; Chen, Yanming

Background and aimsType 2 diabetes mellitus remains a substantial medical problem with increasing global prevalence. Pharmacological research is becoming increasingly focused on personalized treatment strategies. Drug development based on glucokinase (GK) activation is an important strategy for lowering blood glucose. This study aimed to investigate the effect of GK activation on glucose and lipid metabolism in diet-induced obese mice.Materials and methodsMice were fed with a high-fat diet (HFD) for 16 weeks to induce obesity, followed by a GK activator (GKA, AZD1656) or vehicle treatment by gavage for 4 weeks. The effect of GKA treatment on glucose metabolism was evaluated using glucose and insulin tolerance tests. Hepatic lipid accumulation was assessed by hematoxylin and eosin staining, Oil Red O staining, and transmission electron microscopy. The underlying mechanism of GK activation in glucose and lipid metabolism in the liver was studied using transcriptomic analysis, with a mechanistic study in mouse livers in vivo and AML12 cells in vitro.ResultsGK activation by GKA treatment improved glucose tolerance in HFD-fed mice while increasing hepatic lipid accumulation. Transcriptomic analysis of liver tissues indicated the lipogenesis and protein kinase RNA-like endoplasmic reticulum kinase (PERK)-unfolded protein response (UPR) pathway activations in GKA-treated HFD-fed mice. Inhibition of the ACC activity, which is an important protein in lipogenesis, attenuated GKA treatment-induced lipid accumulation and PERK-UPR activation in vitro.ConclusionsGK activation improved glucose tolerance and insulin sensitivity while inducing hepatic lipid accumulation by increasing the lipogenic gene expression, which subsequently activated the hepatic PERK-UPR signaling pathway.

2023-03-01·Aquatic Toxicology

Are we ready to combat the ecotoxicity of COVID-19 pharmaceuticals? An in silico aquatic risk assessment

Article

作者: Khan, Kabiruddin ; Kar, Supratik ; Roy, Kunal

To fight COVID-19 with uncountable medications and bioproducts throughout the world has taken us to another challenge of ecotoxicity. The indiscriminate usage followed by improper disposal of unused antibacterials, antivirals, antimalarials, immunomodulators, angiotensin II receptor blockers, corticosteroids, anthelmintics, anticoagulants etc. can lead us to an unimaginable ecotoxicity in the long run. A series of studies already identified active pharmaceutical ingredients (APIs) of the mentioned therapeutic classes and their metabolites in aquatic bodies as well as in wastewater treatment plants. Therefore, an initial ecotoxicity assessment of the majorly used pharmaceuticals is utmost requirement of the present time. The present in silico risk assessment study is focused on the aquatic toxicity prediction of 81 pharmaceuticals where 77 are most-used pharmaceuticals for COVID-19 throughout the world based on the literature along with one drug nirmatrelvir [PF-07321332] approved for emergency use by US-FDA and three other molecules under clinical trial. The ecotoxicity of the studied compounds were predicted based on the three aquatic species fish, algae and crustaceans employing the highest quality QSAR models available from the literature as well as using ECOSAR and QSAR Toolbox. To compare the toxicity thresholds, we have also used 4 control pharmaceuticals based on the worldwide occurrence from river, lake, STP, WWTPs, influent and effluent followed by high reported aquatic toxicity over the years as per the literature. Based on the statistical comparison, we have proposed top 3 pharmaceuticals used for the COVID-19 most toxic to the aquatic environment. The study will provide confident predictions of aquatic ecotoxicity data related to abundant use of COVID-19 drugs. The major aim of the study is to fill up the aquatic ecotoxicity data gap of major medications used for COVID-19.

项与 AZD-1656 相关的新闻（医药）

2025-02-01

·GlobeNewswire-Health Care

Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence

Conduit is planning how to effectively integrate an advanced platform-driven approach powered by artificial intelligence and cybernetics to expedite drug development, while continuing to advance its portfolio of proprietary assets to clinic. Jan. 28, 2025 -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today is pleased to announce the completion of the first phase of its strategic collaboration with Sarborg Limited. This partnership was initiated in December 2024 to integrate an advanced artificial intelligence and cybernetics technology (“AI”) into the Company’s operations, marking a transformative step in how Conduit would develop and deliver drug development. By leveraging AI, the Company is seeking to streamline drug repurposing, accelerate drug discovery, optimize solid-form identification, and enhance the precision and efficiency of clinical trial monitoring. These advancements are expected to shorten development timelines, reduce costs, and improve the predictability of successful outcomes. Conduit and Sarborg have completed the initial milestones including the Teach-in Sessions and Proprietary Inputs Validation, tailored to Conduit’s portfolio needs. These initial workstreams shape the integration of AI-driven processes to further strengthen Conduit’s ability to advance its proprietary assets, including AZD1656, AZD5904, AZD5658, CDT1656, and its AZD1656 cocrystals, with greater efficiency. While Conduit remains focused on delivering impactful therapies to patients through its proposed Phase 2 clinical trials in auto-immune disorders, the Company continually endeavours to remain at the forefront of innovation in pharmaceutical development. Developing the promising success of the collaboration with Sarborg, Conduit expects AI-driven processes to minimize resource-intensive steps, leading to significant cost savings and fostering the exploration of novel therapeutic avenues previously limited by traditional methods. Building on the foundation work now completed, Conduit will continue to position itself to lead the application of advanced technology within the pharmaceutical sector, ensuring a future defined by faster, more cost-effective, and innovative drug development. Conduit is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, is building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval. The content above comes from the network. if any infringement, please contact us to modify.

临床研究

2024-12-13

·Pharmaceutical Technology

Conduit and Sarborg link to optimise AI drug development

This collaboration is set to transform Conduit’s approach to drug repurposing, discovery and clinical trial monitoring. Credit: MUNGKHOOD STUDIO/Shuterstock. Conduit Pharmaceuticals has signed an agreement with Sarborg to leverage advanced AI and cybernetics for the optimisation of processes related to key drug development. These include the repurposing and discovery of drugs, clinical trial monitoring and solid-form identification. This approach helps to decrease human error, minimise costs and optimise decision-making processes. Conduit’s adoption of these tools will provide a significant competitive advantage by minimising human intervention throughout the drug development cycle. The company will gain access to predictive models and dashboards, allowing for real-time evaluation of drug candidates and the streamlining of clinical trials. Conduit Pharmaceuticals CEO Dr David Tapolczay stated: “By incorporating Sarborg’s cutting-edge AI and cybernetics platform, Conduit is taking a bold step forward in revolutionising our approach to drug development and asset management. “This partnership will provide us with a strategic advantage, allowing us to identify and act on opportunities more swiftly and accurately than ever before.” The integration of learning algorithms is projected to lead to faster, more accurate decisions, thereby improving efficiency and decreasing costs. The partnership grants Conduit a perpetual, royalty-free, assignable and non-exclusive right to utilise any of Sarborg’s platforms or technology. Ongoing support from Sarborg will ensure that these systems evolve in line with Conduit’s needs, fostering long-term innovation in areas such as intellectual property creation and regulatory strategy. By adopting these forward-thinking solutions, Conduit aims to stay at the forefront of innovation, moving away from traditional methods and embracing AI technology. As a multi-asset, clinical-stage, disease-agnostic life science company, the company is focused on delivering an efficient model for compound development. It acquires and funds the development of assets ready for Phase II, and aims for exits through licensing deals post-successful clinical trials. In August 2024, Conduit announced the acquisition of three first-in-class assets , AZD1656, AZD5658 and AZD5904, from AstraZeneca , under an exclusive licensing agreement.

引进/卖出并购

2024-12-03

·PRNewswire

Lupus Nephritis Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain

The lupus nephritis market is poised for growth, driven by rising disease prevalence, advancements in therapeutics such as biologics and targeted therapies, and increased investment in R&D. Heightened awareness and robust support from governments and key industry players further create a dynamic environment for innovation and better patient outcomes. LAS VEGAS, Dec. 3, 2024 /PRNewswire/ -- DelveInsight's ' Lupus Nephritis Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline lupus nephritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the lupus nephritis pipeline domain. Key Takeaways from the Lupus Nephritis Pipeline Report DelveInsight's lupus nephritis pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline therapies for lupus nephritis treatment. Key lupus nephritis companies such as AstraZeneca, Hoffmann-La Roche, Novartis, Qilu Pharmaceutical, Vera Therapeutics, Conduit Pharmaceuticals, Amgen, Johnson & Johnson, BeiGene, RemeGen, Argenx, Kyverna Therapeutics, Cabaletta Bio, ImmPACT Bio, Alpine Immune Sciences, AlloSite Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, Adicet Bio, Shenzhen Pregene Biopharma Co., Ltd., Resolve Therapeutics, BioAegis Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, and others are evaluating new lupus nephritis drugs to improve the treatment landscape. Promising lupus nephritis pipeline therapies such as Anifrolumab, Obinutuzumab, Ianalumab, QLG1074, Atacicept, AZD1656, Daxdilimab, Nipocalimab, Zanubrutinib, Telitacicept, Efgartigimod alfa, KYV-101, CABA-201, IMPT-514, Povetacicept, ONT01, BCMA-CD19 cCAR T cells, CB-010, ADI-001, PRG-2311, RSLV-621, Recombinant human plasma gelsolin, LN-008, TST 008, and others are under different phases of lupus nephritis clinical trials. In November 2024, Adicet Bio announced that the first LN patient had been dosed in the Phase I clinical trial evaluating ADI-001 in autoimmune diseases. In November 2024, Kyverna Therapeutics announced that it would present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase I/II studies and named patient treatments. In October 2024, Kezar Life Sciences suspended subject enrolment and patient dosing in the Phase II PALIZADE trial of zetomipzomib for active lupus nephritis. In June 2024, Nkarta announced the initiation of Ntrust-I, a multi-center clinical trial of NKX019 in lupus nephritis, with the first patient in screening. The company also announced the clearance by the U.S. Food and Drug Administration (FDA) of its second Investigational New Drug (IND) application for NKX019 in autoimmune disease. In June 2024, Adicet Bio announced that the US Food and Drug Administration (FDA) had granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis. In April 2024, Caribou Biosciences announced that it had received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024. In March 2024, Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in lupus nephritis (LN). Request a sample and discover the recent advances in lupus nephritis treatment drugs @ Lupus Nephritis Pipeline Report The lupus nephritis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage lupus nephritis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the lupus nephritis clinical trial landscape. Lupus Nephritis Overview Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease that can affect multiple organ systems. In lupus nephritis, the immune system mistakenly attacks the kidneys, leading to inflammation and damage. The exact cause is not fully understood, but it is believed to involve a combination of genetic, hormonal, and environmental factors, including infections and exposure to certain drugs or UV light. Symptoms of lupus nephritis can vary but often include swelling in the legs and feet, high blood pressure, foamy urine, and in severe cases, hematuria. Patients may also experience fatigue, joint pain, and skin rashes, typical of lupus. Diagnosis usually involves a combination of blood tests, urinalysis, and imaging studies. A kidney biopsy may be necessary to evaluate the extent of kidney damage and guide treatment. Treatment for lupus nephritis aims to reduce inflammation and prevent kidney damage. It often involves corticosteroids and immunosuppressive medications such as mycophenolate mofetil or azathioprine. In severe cases, more aggressive treatments, including cyclophosphamide or biologic therapies like belimumab, may be utilized. Regular monitoring of kidney function and overall health is crucial for managing the disease effectively. Find out more about lupus nephritis treatment drugs @ Drugs for Lupus Nephritis Treatment A snapshot of the Lupus Nephritis Pipeline Drugs mentioned in the report: Learn more about the emerging lupus nephritis pipeline therapies @ Lupus Nephritis Clinical Trials Lupus Nephritis Therapeutics Assessment The lupus nephritis pipeline report proffers an integral view of the lupus nephritis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Lupus Nephritis Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Interferon alpha-beta receptor antagonists, Cell death inhibitors, Cell death stimulants, Antibody-dependent cell cytotoxicity, B-cell activation factor receptor antagonists, Glucokinase stimulants, Dendritic cell inhibitors, Complement factor D inhibitors, Complement C3 inhibitors, Proteasome inhibitors, Natural killer cell replacements, Immunologic cytotoxicity; T lymphocyte replacements Key Lupus Nephritis Companies: AstraZeneca, Hoffmann-La Roche, Novartis, Qilu Pharmaceutical, Vera Therapeutics, Conduit Pharmaceuticals, Amgen, Johnson & Johnson, BeiGene, RemeGen, Argenx, Kyverna Therapeutics, Cabaletta Bio, ImmPACT Bio, Alpine Immune Sciences, AlloSite Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, Adicet Bio, Shenzhen Pregene Biopharma Co., Ltd., Resolve Therapeutics, BioAegis Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, and others. Key Lupus Nephritis Pipeline Therapies: Anifrolumab, Obinutuzumab, Ianalumab, QLG1074, Atacicept, AZD1656, Daxdilimab, Nipocalimab, Zanubrutinib, Telitacicept, Efgartigimod alfa, KYV-101, CABA-201, IMPT-514, Povetacicept, ONT01, BCMA-CD19 cCAR T cells, CB-010, ADI-001, PRG-2311, RSLV-621, Recombinant human plasma gelsolin, LN-008, TST 008, and others. Dive deep into rich insights for new drugs for lupus nephritis treatment, visit @ Lupus Nephritis Drugs Table of Contents For further information on the lupus nephritis pipeline therapeutics, reach out @ Lupus Nephritis Treatment Drugs Related Reports Lupus Nephritis Epidemiology Lupus Nephritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted lupus nephritis epidemiology in the 7MM. Lupus Nephritis Market Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including NOVARTIS, MORPHOSYS, ASTRAZENECA, ROCHE, KEZAR LIFE SCIENCES, ALEXION PHARMACEUTICALS, CABALETTA BIO, among others. Systemic Lupus Erythematosus Market Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SLE companies, including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others. Systemic Lupus Erythematosus Pipeline Systemic Lupus Erythematosus Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio, Pfizer, Novartis, Neovacs, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床申请

100 项与 AZD-1656 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14810

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病	临床2期	英国	St George Street Capital Ltd.	2021-11-01
糖尿病	临床2期	英国	Barts Health NHS Trust	2021-11-01
抗中性粒细胞胞质抗体相关性血管炎	临床2期	美国	Conduit Pharmaceuticals, Inc.	-
狼疮性肾炎	临床2期	美国	Conduit Pharmaceuticals, Inc.	-
新型冠状病毒感染	药物发现	英国	St George Street Capital Ltd.	2020-08-12
新型冠状病毒感染	药物发现	捷克	St George Street Capital Ltd.	2020-08-12
新型冠状病毒感染	药物发现	罗马尼亚	St George Street Capital Ltd.	2020-08-12
终末期肾脏病	药物发现	英国	AstraZeneca PLC	2019-12-13
移植并发症	药物发现	英国	AstraZeneca PLC	2019-12-13
2型糖尿病	药物发现	美国	AstraZeneca PLC	2009-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04516759 (ARCADIA, Pubmed) 人工标引	临床2期	新型冠状病毒感染 \| 糖尿病	153	AZD-1656	(糧鬱鬱夢糧膚選鹽鬱積) = 廠構範繭簾衊鏇淵觸願艱鑰選蓋艱壓繭蓋積艱 (餘糧窪鏇蓋網獵艱積膚 ) 更多	不佳	2022-08-18
				Placebo	(糧鬱鬱夢糧膚選鹽鬱積) = 廠範廠餘襯鏇構餘構願艱鑰選蓋艱壓繭蓋積艱 (餘糧窪鏇蓋網獵艱積膚 ) 更多
NCT04516759 (ARCADIA, CTgov)	临床2期	新型冠状病毒感染	170	AZD1656 (AZD1656 (Plus Usual Hospital Care))	淵鏇壓淵遞淵願窪窪製(壓廠繭蓋餘憲憲顧積衊) = 鹹憲鬱壓築鬱網憲遞獵壓積艱鹽選糧鏇積鹽觸 (鏇遞鏇簾淵築鬱廠構淵, 糧廠構積憲壓鏇觸構壓 ~ 廠製艱顧糧餘鬱鏇齋糧) 更多	-	2022-04-25
				Placebo (Matched Placebo (Plus Usual Hospital Care))	淵鏇壓淵遞淵願窪窪製(壓廠繭蓋餘憲憲顧積衊) = 壓遞廠製鹹鏇範餘製網壓積艱鹽選糧鏇積鹽觸 (鏇遞鏇簾淵築鬱廠構淵, 壓鹹餘膚醖壓鏇襯壓淵 ~ 壓艱衊鏇蓋齋網醖齋衊) 更多
NCT01152385 (Pubmed \| Diabetes Obes Metab)	临床2期	2型糖尿病	224	AZD1656 40-200 mg	(醖廠鏇蓋鏇構夢壓獵製) = 網鹽鹹範膚衊齋鏇壓蓋壓蓋憲製糧淵範鹽窪憲 (淵選襯壓艱鏇顧獵醖糧, ( ~ 0.65, 0.20))	-	2013-10-01
				Placebo	(醖廠鏇蓋鏇構夢壓獵製) = 鬱鹹齋餘艱範襯齋壓衊壓蓋憲製糧淵範鹽窪憲 (淵選襯壓艱鏇顧獵醖糧 )
NCT01020123 (CTgov)	临床2期	2型糖尿病	530	AZD1656+metformin (Higher Dose)	觸廠鏇憲艱膚蓋鏇蓋壓(鬱齋顧範繭製齋襯鏇憲) = 網築範糧鹹鹹艱獵艱顧網醖糧鏇鏇糧遞夢窪艱 (襯願鏇遞積憲鏇構網簾, 鬱網齋鏇廠襯觸鑰鏇遞 ~ 製鑰鑰憲夢觸夢襯醖顧) 更多	-	2012-11-26
				AZD1656+metformin (Lower Dose)	觸廠鏇憲艱膚蓋鏇蓋壓(鬱齋顧範繭製齋襯鏇憲) = 構襯壓膚顧獵觸獵築鏇網醖糧鏇鏇糧遞夢窪艱 (襯願鏇遞積憲鏇構網簾, 鹽繭糧觸餘鏇鑰鏇襯壓 ~ 齋壓鏇壓鬱構襯鏇獵選) 更多
NCT00856908 (CTgov)	临床2期	2型糖尿病	20	AZD1656 (Experimental)	齋壓積糧鬱憲糧獵醖製(衊壓積憲鑰鹹鑰衊繭繭) = 餘淵選獵選醖範窪壓憲衊淵膚構壓糧夢鹹顧膚 (夢窪醖築醖廠鹹獵鑰窪, 簾繭鏇窪獵窪糧構願構 ~ 繭遞選蓋繭淵窪餘鹽顧) 更多	-	2012-11-26
				placebo (Placebo Comparator)	齋壓積糧鬱憲糧獵醖製(衊壓積憲鑰鹹鑰衊繭繭) = 蓋築製蓋鏇窪製網鏇壓衊淵膚構壓糧夢鹹顧膚 (夢窪醖築醖廠鹹獵鑰窪, 蓋窪糧壓鏇繭觸齋鑰餘 ~ 醖網膚蓋膚鏇餘鏇艱鏇) 更多